Salivary and urinary hormone testing to guide hormone therapy dosing is considered unreliable and is not recommended by major guideline bodies, because serum, saliva, and tissue levels differ substantially, the tests are affected by time-of-day variation and large individual variability, and no validated assay has been shown to correspond to an actual clinical outcome like bone protection, endometrial protection, or symptom control.

Even for the more standard measure, serum progesterone, there is an important finding here: one major trial found the endometrium was protected at serum progesterone levels far below what a luteal-phase target would be, which means titrating progesterone dose to hit a specific blood number is not what the trial evidence actually supports either.

What to know about this answer

The mainstream position, that saliva and urine hormone testing should not be used to guide dosing, is nearly unanimous among the clinicians in this material; the strongest counterargument is about patient autonomy rather than about the tests actually being accurate.

What the research shows, and which source each finding rests on

Salivary hormone testing to guide hormone therapy dosing is unreliable and is not recommended by major guideline bodies

A[1]A[2]

In a trial of continuous-combined oral estradiol/progesterone, endometrial protection occurred with serum progesterone of only 0.39 to 0.55 ng/mL over 12 months, far below luteal-phase levels, meaning serum progesterone concentration is a poor proxy for whether the endometrium is actually protected

B[3]

Where the real disagreement is

Each position is shown with its own sources. A position listed here is not necessarily the accepted view.

Saliva and urine testing are unreliable and should not guide dosing

Nearly every clinician in the field and major guideline bodies

The decisive problem is not just assay precision, it's that even a perfectly precise saliva measurement is useless without proof that a given saliva value corresponds to a real outcome like bone protection or endometrial protection, and no such outcome studies exist. One clinician names a red-flag pattern worth watching: a saliva testing lab charging very high fees is very suspect.

A[1]A[2]

Some women feel reassured by testing and should retain the choice

A patient-autonomy framing offered alongside the mainstream caution

Naming the red flags around expensive saliva testing does not mean a woman can't choose to do it if it's working for her and she's happy; she has body autonomy, but she should know the red flags exist before deciding.

A[1]

What would settle it: Validated assays with demonstrated correspondence to real clinical outcomes, bone density, endometrial safety, symptom control, would be needed before hormone-level testing could reasonably guide dosing decisions; no such validation currently exists for saliva or urine testing.

What is really going on here

  1. Has this hormone test, saliva, urine, or blood, been shown to predict a real clinical outcome, like endometrial or bone protection, or is it just a number with no proven meaning?
  2. Is my dose being titrated to hit a specific blood or saliva target, when the trial evidence shows protection can occur at levels far below that target?
  3. If I'm on transdermal progesterone cream, has my endometrial protection actually been confirmed some other way, since saliva levels alone don't establish that?
  4. Is the lab or clinic recommending this testing charging unusually high fees?

Questions for your doctor

  1. Is there a proven clinical reason to test my hormone levels, or are we testing without a clear plan for what we'd do with the number?
  2. If I have a uterus, how exactly is my endometrium being protected, and is that method's evidence based on outcome data rather than a hormone level target?
  3. If you recommend blood testing rather than saliva, what specifically will the result change about my treatment?
  4. Is there a reason to avoid transdermal progesterone cream specifically, given the endometrial protection concern?

Questions with no answer yet

Does any hormone level, measured by any method, actually predict which women will develop endometrial hyperplasia, bone loss, or symptom recurrence, or is level-based dosing a widely practiced convention that has never been validated against a real outcome?

Partly studied

What is known: One major trial found the endometrium was protected at serum progesterone levels far below what a luteal-phase target would be, directly showing that serum progesterone concentration is a poor proxy for whether the endometrium is actually protected; no validated assay of any kind has been shown to correspond reliably to bone protection, endometrial protection, or symptom control across the board.

What would test it: Prospective validation studies linking specific hormone levels, by any testing method, to directly measured clinical outcomes rather than assuming a level-to-outcome relationship.

Does transdermal progesterone cream fail to protect the endometrium because the hormone does not reach the uterus systemically, or because the salivary levels it produces do not reflect what is actually happening in uterine tissue?

Partly studied

What is known: The source material describes transdermal progesterone cream as not reliably protecting the endometrium despite producing detectable, sometimes high, salivary levels, but flags that the specific primary trial establishing this needs direct citation and verification before being treated as settled.

What would test it: A verified, adequately powered trial directly measuring endometrial outcomes in women using transdermal progesterone cream, with paired salivary and tissue-level data.

Sources

  1. 1.The 2022 hormone therapy position statement of The North American Menopause Society.The 2022 hormone therapy position statement of The North American Menopause Society. Menopause 2022;29(7):767-794. · Systematic review or guideline
  2. 2.Compounded Bioidentical Menopausal Hormone Therapy: ACOG Clinical Consensus No. 6.Compounded Bioidentical Menopausal Hormone Therapy: ACOG Clinical Consensus No. 6. Obstet Gynecol 2023;142(5):1266-1273. · Systematic review or guideline
  3. 3.Estradiol and progesterone bioavailability for moderate to severe vasomotor symptom treatment and endometrial protection with the continuous-combined regimen of TX-001HR (oral estradiol and progesterone capsules).Lobo RA, et al. Estradiol and progesterone bioavailability for moderate to severe vasomotor symptom treatment and endometrial protection with the continuous-combined regimen of TX-001HR (REPLENISH). Menopause 2019;26(7):720-727. · Randomised trial

The letter grades the type of study behind a claim, not the answer itself.

This page is general information based on published research and public sources. It is not medical advice and not a personal assessment, and it does not replace a conversation with your doctor. Peritale is a wellness product, not a medical device, and is not intended to diagnose, treat, cure or prevent any disease. For any medical question, speak with a licensed clinician.

You are not imagining it

In about seven minutes on your phone, Peritale reads five signal systems and maps your symptoms, so you can see that what you feel is real, follow your hormonal transition over time, and walk into your doctor ready to ask for the care you deserve. Your first check is free, no credit card.

Start Free Mapping

Related questions

Related guides